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Abstract
Deficiency of the transcription factor GATA2 is a highly penetrant genetic disorder predisposing to myelodysplastic
syndromes (MDS) and immunodeficiency. It has been recognized as the most common cause underlying primary MDS in
children. Triggered by the discovery of a recurrent synonymous GATA2 variant, we systematically investigated 911 patients
with phenotype of pediatric MDS or cellular deficiencies for the presence of synonymous alterations in GATA2. In total, we
identified nine individuals with five heterozygous synonymous mutations: c.351C>G, p.T117T (N= 4); c.649C>T, p.L217L;
c.981G>A, p.G327G; c.1023C>T, p.A341A; and c.1416G>A, p.P472P (N= 2). They accounted for 8.2% (9/110) of cases
with GATA2 deficiency in our cohort and resulted in selective loss of mutant RNA. While for the hotspot mutation
(c.351C>G) a splicing error leading to RNA and protein reduction was identified, severe, likely late stage RNA loss without
splicing disruption was found for other mutations. Finally, the synonymous mutations did not alter protein function or
stability. In summary, synonymous GATA2 substitutions are a new common cause of GATA2 deficiency. These findings
have broad implications for genetic counseling and pathogenic variant discovery in Mendelian disorders.
Introduction
Germline mutations in the GATA2 gene, mostly arising
de novo, had been reported to cause an immunodeficiency/
myelodysplasia syndrome manifesting with a multitude of
clinical phenotypes. These include monocytopenia and
mycobacterial infections syndrome (MonoMAC syndrome)
[1], dendritic cell, monocyte, B and NK lymphoid defi-
ciency (DCML deficiency) [2], familial myelodysplastic
syndrome (MDS)/acute myeloid leukemia (AML) [3],
chronic neutropenia [4], Emberger syndrome [5] and warts,
immunodeficiency, lymphedema and anogenital dysplasia
syndrome (WILD syndrome) [6]. Finally, GATA2 deficiency
is considered the most common hereditary predisposition to
pediatric MDS, accounting for as much as 15% of MDS with
excess of blasts (MDS-EB), with a particularly high pre-
valence among MDS patients carrying monosomy 7 (37%)
[7]. To date, more than 400 GATA2-deficient cases have
been published [8, 9] with three major types of pathogenic
GATA2 mutations: (1) missense mutations within zinc finger
2 (ZnF2), (2) null mutations (splice site, nonsense, frame-
shift, and whole gene deletions), and (3) noncoding sub-
stitutions in the EBOX-GATA-ETS regulatory region in
intron 4 (hg19, g.128202128-128202173, NM_032638.4)
[8–10]. Overall, germline GATA2 mutations are thought to
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result in haploinsufficiency and context-dependent loss of
essential transcription factor activity [3, 5, 11–14].
Genomic studies typically focus on the discovery of
nonsynonymous variants that alter coding regions or
canonical splice sites because their effect is predictable.
Conversely, due to codon degeneracy, synonymous sub-
stitutions do not alter the amino acid composition of the
encoded protein and are usually not reported as pathogenic.
However, previous studies revealed that such variants can
alter RNA or protein on multiple levels including pre-
mRNA splicing, messenger RNA (mRNA) stability and
structure, miRNA binding, and translation [15–24].
Here, we initially identified a synonymous substitution in
exon 3 of the GATA2 gene (c.351C>G, p.T117T) in two
unrelated pedigrees, with the clinical phenotype of GATA2
deficiency. The variant was recently reported in an adult
patient (the mother of two siblings studied here) presenting
with immunodeficiency, severe infections and lung disease
[25]. This prompted us to study the contribution of synon-
ymous alterations to the genetic spectrum of GATA2 defi-
ciency and to assess their pathogenic role. We discovered
and characterized five distinct synonymous mutations with
RNA-deleterious effect in nine patients. They represent a
new type of mutation in GATA2 deficiency and have broad
implications for both the discovery of disease-causing
mutations and genetic counseling.
Methods
Patient cohort and genomics
The screening cohort consisted of 911 patients (Fig. 1a):
729 children and adolescents with primary MDS classified
according to WHO criteria [26–28] enrolled in the studies
1998 and 2006 of the European Working Group of MDS in
Childhood (EWOG-MDS, #NCT00662090), and 182
patients with cytopenias and/or GATA2-specific clinical
problems, referred to our diagnostic laboratory. GATA2
gene sequence, including intron 4 was analyzed in bone
marrow (BM) samples using targeted deep sequencing with
Sanger sequence validation, and subsequent confirmation of
germline mutational status in nonmyeloid tissues as pre-
viously reported [7, 29]. Whole exome/genome sequencing
(WES/WGS) was performed in patients with synonymous
GATA2 variants to rule out other hereditary causes (Sup-
plementary methods, Supplementary Table 1).
Targeted investigations of GATA2 transcript
expression
We analyzed RNA expression in blood, BM or fibroblasts
using Sanger, deep sequencing, and TA cloning-based
sequencing (Supplementary methods, Supplementary Fig. 1
and Supplementary Table 2). In addition, GATA2 expres-
sion in various hematopoietic compartments of healthy
controls was measured (Supplementary methods).
Studies of GATA2 protein stability and function
In order to explore the influence of synonymous mutations
on protein stability and function, in vitro analysis of exo-
genously expressed GATA2 was performed in 293T cells.
To further investigate the protein function, in vivo studies in
zebrafish were accomplished (for details see Supplementary
methods). Experiments were performed in duplicates or
triplicates as indicated in the figure legends.
Statistics
For reporter assay, data from biological and technical tri-
plicate experiments were presented as the mean values ±
standard deviation (SD). Statistical significance was asses-
sed using GraphPad Prism v 7.04 software employing either
standard one-way ANOVA test (reporter assay, thermo-
dynamic effect of GATA2 variants) or Student’s t test
(allele quantification in patients’ cDNA by deep sequen-
cing, frequency of zebrafish phenotypes). P values < 0.05
were considered statistically significant.
Results
Identification of synonymous GATA2 variants
We initially discovered two unrelated individuals (P1, P3)
with GATA2 deficiency carrying an identical synonymous
GATA2 variant. This prompted a systematic evaluation of the
GATA2 gene sequence in our screening cohort of patients
presenting for the most part with the phenotype of pediatric
MDS (Fig. 1a). At first, we categorized “classical” disease-
causing alterations and identified 101 patients with 62 dis-
tinct pathogenic GATA2 mutations (Fig. 1a). The distribution
of mutations corroborated data reported in previous studies
[9]. The most common were null mutations affecting the N-
terminal part of the protein: stop-gain, frameshift, splice site
(N= 52), followed by missense mutations within or adjacent
to ZnF2 (N= 36), intron 4 EBOX-GATA-ETS site altera-
tions (N= 10), and other aberrations (N= 3): one in-frame
and two whole gene deletions (Fig. 1b).
Next, we searched GATA2 coding sequence for the pre-
sence of synonymous substitutions. Variants that are either
not reported or very rare (<0.05% allele frequency) in the
gnomAD population database were found in nine patients.
These variants were present in 8.2% (9/110) of all patients
with GATA2 alterations, and 14.8% (9/61) of cases with
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GATA2 exonic substitutions only (Fig. 1c). In comparison,
common polymorphisms with synonymous effect p.P5P, p.
P22P, p.Q38Q, p.T188T, and p.A411A were not sig-
nificantly enriched in our cohort (not shown), arguing
against their disease-causing role in MDS.
The synonymous substitutions encountered in P1–P9
were predicted to have a likely benign effect using the
combined annotation-dependent depletion score (CADD)
and gene-specific calibration by Gene-Aware Variant
INterpretation (GAVIN) (Table 1). The evolutionary
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Fig. 1 Composition and genetics of the study cohort. a Flow dia-
gram depicts the screening cohort and GATA2 mutations identified. b
Overall distribution of genotypes among 110 patients with GATA2
deficiency. Truncating variants are localized prior to or within zinc
finger 2; missense mutations cluster mainly to zinc finger 2 region;
intron 4 mutations affect the EBOX-GATA-ETS regulatory region
(+9.5 kb) of GATA2; other: one in-frame deletion and two whole gene
deletions; synonymous variants are proposed as a new group of
pathogenic GATA2 mutations. Numbers in parentheses refer to indi-
vidual patients. c Frequency of patients with synonymous mutations
among all GATA2 positive cases and among the group of patients
carrying exonic substitutions. d Schematic representation of the
GATA2 gene (NM_032638.4) with synonymous variants identified.
Affected nucleotide is shaded blue and dashed line boxes indicate
respective codon triplet. Nucleotide conservation is presented for nine
species. Evolutionary conservation is depicted on the bottom as
Genomic Evolutionary Rate Profiling (GERP++RS) score with
values ranging from −12.36 to 6.18, and 6.18 being the most con-
served. Splicing prediction was performed with Human Splicing Fin-
der v.3.0. ESS exonic splicing silencer, ESE exonic splicing enhancer.
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nucleotide conservation was high for c.351 and c.649
nucleotides (Fig. 1d), suggesting their resistance to evolu-
tionary change. Splicing prediction tools assigned a high
chance of splice defects to c.351C>G, c.981G>A, and
c.1023C>T variants either via activation of a cryptic donor,
introduction of an alternative splicing silencer or disruption
of an existing splicing enhancer (Fig. 1d, Supplementary
Fig. 2, and Table 1).
Phenotype of patients with synonymous GATA2
mutations
Patients with synonymous GATA2 mutations were diagnosed
at a median age of 11.5 (3–24) years. Hematologic and
immunological phenotypes were consistent with the hetero-
geneous clinical picture of GATA2 deficiency and included
varying degrees of immune cytopenias (low B/NK, DC cells,
monocytopenia), immunodeficiency, neutropenia, and/or
pancytopenia (supplemental case descriptions). P2 is the
sibling of GATA2-deficient patient P1 and was categorized
as a silent GATA2mutation carrier with a reduction of B- and
NK-cells. Their mother was previously reported with pul-
monary alveolar proteinosis [25]. P7 and P8 (unrelated,
carrying the same mutation), initially presented with throm-
bocytopenia and while P8 developed transfusion-dependent
refractory cytopenia of childhood (RCC), P7 remained stable
with BM morphology suspicious for RCC. P9 was first seen
with complications of immunodeficiency and clinically
evolved to MDS. Monosomy 7 in BM was detected at
diagnosis in four patients (P1, P3, P4, and P6), normal kar-
yotypes were present in four (P5, P7, P8, and P9), while no
marrow exam was performed in P2 (Table 2). According to
the WHO classification, P1 and P4–P8 were diagnosed with
RCC, and P9 with MDS with multilineage dysplasia as a
young adult. Initial disease of P3 was MDS-EB, which
progressed to AML after 6 months. Other clinical problems
in the affected patients were transient organ dysfunction after
birth and facial abnormalities in P4, hepatosplenomegaly in
P5, hypospadias in P6, and Crohn’s colitis as well as HPV-
driven neoplasia in P9. The majority of patients (6/9)
underwent allogeneic hematopoietic stem cell transplantation
(HSCT) with favorable outcome: 5/6 patients were alive at
last follow up (at a median of 1.9 years after HSCT) and 1/6
(P3) died from infection 7 months following HSCT
(Table 2).
Exclusion of other hereditary causes
We next aimed to determine if other genetic conditions
predisposing to inherited bone marrow failure (IBMF) or
Table 1 Synonymous variants identified in MDS patients.
Patient
no. (ID)
GATA2
mutation
Genomic DNA
VAF%
(total depth)
cDNA VAF%
WT/Mut
(total depth)
Evol conser/
PhysChem diff
CADD/GAVIN
(C2; P > 26, B <
19)
gnomAD browser
MAF% (mutant/
total)
Splicing
prediction
P1 (D 1239) c.351C>G;
p.T117T
WES50% (160),
DS47% (766)
DS99.88%/0.006%
(320215)
Medium/none 10.5/B None Cryptic donor,
new ESS site
P2
(sister of P1)
c.351C>G;
p.T117T
Heterozygous
(Sanger)
Not done As above As above As above As above
P3 (D 749) c.351C>G;
p.T117T
WES47% (130),
DS51% (703)
DS99.89%/0.004%
(838094)
As above As above As above As above
P4 (LT) c.649C>T;
p.L217L
WES48% (196),
DS51% (725)
DS79.43%/20.56%
(429616)
High/none 10.7/B 0.001% (2/246096) None
P5 (D 722) c.981G>A;
p.G327G
WES52% (156),
DS48% (788)
DS99.96%/0.014%
(7190)
Medium/none 18.5/B None New ESS site
P6 (D 1142) c.1023C>T;
p.A341A
WES47% (296),
DS49% (1449)
DS99.91%/0.095%
(4213)
Weak/none 15.4/B 0.002% (6/275438) ESE
site broken
P7 (D) c.1416G>A;
p.P472P
WES49% (63) DS99.91%/0.085%
(388784)
Medium/none 12.4/B 0.027% (70/256322) None
P8 (I 386) c.1416G>A;
p.P472P
Heterozygous
(Sanger)
Not done As above As above As above As above
P9
(UKA2604)
c.351C>G;
p.T117T
Heterozygous
(Sanger)
Not done Medium/none 10.5/B None Cryptic donor,
new ESS site
Gene annotation: GATA2 (NM_032638.4).
VAF variant allelic frequency, WT wild-type allele, Mut mutated allele, WES whole exome sequencing, DS deep sequencing, Sanger identified by
Sanger sequencing, Evol (evolutionary) conservation assessed using Phylop and PhastCons, PhysChem diff physicochemical difference between
amino acids, CADD combined annotation-dependent depletion score, GAVIN Gene-Aware Variant Interpretation (C2: CADD scores significantly
predictive for pathogenicity (p < 0.05), P pathogenic if CADD > 26, B benign if CADD lower than 19), MAF minor allelic frequency, Splicing
prediction Human Splicing Finder v. 3.0. ESS exonic splicing silencer, ESE exonic splicing enhancer.
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MDS might have been previously missed in our patients.
WES/WGS was performed in all families with exception of
P8 who was assessed by a 135 IBMFS/MDS gene panel.
The WES analysis focused on known IBMF/MDS and
pancancer genes (300 genes) [26, 30]. Multiple hetero-
zygous variants of uncertain significance (VUS) were
identified (Supplementary Table 1). After comprehensive
review by a multidisciplinary board representing pediatric
hematology, genetic counseling, and molecular biology,
only P6 remained with additional potentially pathogenic
SAMD9 variants p.K877E and p.F366LfsX33. This patient
did not have features typical for MIRAGE syndrome, which
was initially ascribed to SAMD9 mutations [31, 32]. Nota-
bly, we discovered VUS in the Fanconi anemia (FA) genes
FANCD1, FANCD2, and FANCS in three patients. How-
ever, these VUS were heterozygous and FA was ruled out in
all three patients by means of chromosomal breakage stu-
dies and clinical phenotyping.
Synonymous GATA2 variants result in selective loss
of mRNA expression
Building on the assumption that synonymous variants
detected in our patients were associated with degradation of
the mutant (Mut) mature mRNA, we first sequenced cDNA
transcribed from polyadenylated RNA transcripts (equiva-
lent to mRNA) using Sanger method. Compared with
genomic DNA, cDNA sequences showed loss of hetero-
zygosity manifested by complete lack of the Mut allele in
five out of seven cases: P1, P3, P5, P6, and P7, and a
substantial reduction in P4 and P9 (Fig. 2a upper panel).
Compared with hematopoietic specimens, Mut allele
expression was slightly higher in skin fibroblasts of P1 and
P4 (Fig. 2a lower panel). Because it is not known if
monoallelic GATA2 expression might be a general phe-
nomenon in normal hematopoiesis, we sequenced three
healthy controls who carried a common heterozygous
polymorphism (rs2335052: c.490G>A; p.A164T). Both the
genomic DNA and cDNA showed an equal ratio of alter-
native to reference alleles (Fig. 2b).
Deep sequencing based quantification of allelic fre-
quency showed nearly total absence of Mut alleles in P1,
P3, P5–P7, and a reduction of Mut expression to 21% in P4
(Table 1 and Fig. 2c). Combined across all samples, we
observed median values of 27 reads for Mut, versus
330,544 reads for wild-type (WT) alleles. Lastly, TA
cloning of P5’s and P6’s cDNA followed by sequencing of
an average of 345 single colonies was a third independent
method confirming the RNA reduction (0% and 11% of
Mut amplicons for P5 and P6, respectively, not shown). In
order to address at which stage of RNA maturation the Mut
alleles were lost, we deep sequenced products that were
reverse-transcribed using alternative priming approaches.
While oligo(dT) that are specific to mature transcripts
(mRNA) produced almost exclusively GATA2 WT reads,
the use of random hexamers (enriching both pre-mRNA and
mRNA) resulted in an increase of Mut reads to ~30% for P1
and P6 (Fig. 2d).
Splicing analysis of the GATA2 gene
In order to ascertain the mechanism of monoallelic GATA2
expression, RNA sequencing (RNAseq) was performed in
sorted CD34+ BM cells of five patients (P1, P4–P7).
Table 2 Clinical characteristics of patients with synonymous GATA2 mutations.
Patient no. (ID) Age at Dx Sex Hematological presentation and other features Karyotype Therapies Age and status
at last FUP
P1 (D 1239) 12 F RCC, low IgG, low monocytes/B/DC −7 MUD-HSCT 13.5 years: alive
P2 (sister of P1) 11 F B/NK-cell lymphopenia, low IgA/G Not done Observation 12 years: alive
P3 (D 749) 14 F MDS-EB −7 CB-HSCT 15.4 years: died from
infection 7 months
after HSCT
P4 (LT) 3 M RCC, facial abnormalities, skin
hypopigmentation, joint hypermobility
−7 MSD-HSCT 7.6 years: alive
P5 (D 722) 11 M RCC, hepatosplenomegaly Normal Observation 18.5 years: alive
P6 (D 1142) 11.5 M RCC, hypospadias −7 MUD-HSCT 15.2 years: alive
P7 (D) 14 F Suspicious for RCC Normal – 20.9 years: alive
P8 (I 386) 4 F RCC Normal MUD-HSCT 4 years: alive
P9 (UKA2604) 24 F MDS-MLD, low monocytes/B/NK/DC,
recurrent viral warts, mycobacterium avium
infections, HPV-driven neoplasia, Crohn’s colitis
Normal MUD-HSCT 32 years: alive
Dx diagnosis, RCC refractory cytopenia of childhood, DC dendritic cells, NK natural killer cells, MDS-EB myelodysplastic syndrome with excess
blast, MDS-MLD myelodysplastic syndrome with multilineage dysplasia, HSCT allogeneic hematopoietic stem cell transplantation, −7 monosomy
7, MUD matched unrelated donor, CB cord blood, MSD matched sibling donor, FUP follow-up.
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Isoform analysis revealed two novel splice junctions in P1,
not observed in the Ensembl database and healthy controls
(Fig. 3a and Supplementary Fig. 3). In both new transcripts
in P1 the c.351C>G mutation acts as a new splice donor that
joins to alternative acceptors either at c.488 or at c.608.
Long range RT-PCR and sequencing in P1′ BM and
fibroblasts (Fig. 3b) confirmed the presence of the transcript
with c.488 alternative acceptor. Finally, TA cloning of the
cDNA PCR products of P1 and sequencing of 348 colonies
revealed the presence of three novel transcripts (Fig. 3c).
Two of these were identical as detected by RNAseq; the
third transcript found in only nine colonies harbors the
c.351 donor that joins to a new splice acceptor at position
c.539. All three transcripts resulted in sequence frameshift
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Fig. 2 Sequencing analysis of patients with synonymous GATA2
mutations. a Upper panel: Representative electropherograms with
genomic and cDNA sequence surrounding the affected nucleotide (red
line). All five distinct synonymous mutations are represented. Lower
panel: Comparison of allelic expression in the hematopoietic and
nonhematopoietic tissue of P1 and P4. b Genetic testing of healthy
controls carrying a common nonsynonymous GATA2 polymorphism
c.490G>A (19.5% minor allele frequency in gnomAD). c Allelic fre-
quency of GATA2 alleles determined by targeted deep sequencing of
patients’ cDNA; numbers of reads taken from one representative
replicate. In all cases oligo(dT) priming was used with exception of P4
and P5 (*) where the mixture of random hexamers and oligo(dT) was
utilized. Outside right: Boxplot depicts combined allelic contribution
in all patients. Calculation of p value was performed using Student’s t
test (mean ± SD values). d Frequency of mutated alleles determined by
deep sequencing of cDNA obtained from bone marrow RNA using
two different reverse transcription priming methods. Mutant vs. total
read counts are shown in parentheses, and percentage represents the
proportion of mutated alleles in the sample. BM bone marrow, Fib
fibroblasts, PB peripheral blood.
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and occurrence of a premature stop codon at c.650. No new
isoforms were found in P4–P7 by RNAseq; additional TA
cloning and sequencing of cDNA in P5 and P6 detected
only properly spliced full length transcripts.
Synonymous variants are predicted not to affect
RNA stability
The impact of synonymous variants on mRNA stability
and secondary structure was determined using Mfold,
RNAfold, and Quickfold tools. Synonymous substitutions
were predicted not to significantly affect secondary struc-
ture of mRNA (Supplementary Fig. 4a). In addition, no
relevant energy change (ΔG) was observed between Mut
and WT (Supplementary Fig. 4b). As a comparison, five
common synonymous polymorphisms from GnomAD and
five nonsynonymous pathogenic GATA2 mutations were
included in the analysis. None of these variants had
influence on the mRNA structure and thermodynamic
characteristics.
Analysis of protein stability and function
We investigated the levels of endogenous GATA2 protein
in P9 who carried RNA-deleterious mutation c.351C>G, p.
T117T and had sufficient primary specimen. Analysis was
performed in patient-derived platelets since GATA2 was
previously found to be highly expressed in this hemato-
poietic subpopulation (Supplementary Fig. 5) [33, 34].
GATA2 protein levels were severely reduced, similarly
to other known pathogenic GATA2 mutations (Fig. 4a).
Next, to determine the effect of the synonymous variants
on GATA2 transcriptional function, GATA-specific
reporter assay was performed. Transactivation activity
was comparable between synonymous Mut and WT
(Fig. 4b). We subsequently assessed the protein:DNA-
binding ability using the electrophoretic mobility shift
assay (EMSA) for the mutation c.649C>T, p.L217L. Using
this limited approach, no significant difference in DNA
binding between Mut and WT GATA2 proteins was seen
(Fig. 4c). Of note, both functional experiments were
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performed at steady state with a high level of ectopic
protein expression.
Because it is known that synonymous variants can impair
translation, we aimed to analyze the effect of Muts on
protein levels. We ectopically expressed cDNA under the
principle that splicing effect will not be expected due to
missing introns, and observed protein changes will result
from altered translation. We blocked the transcription with
actinomycin D in transfected 293T cells and analyzed
protein levels over time (Fig. 4d). Expectedly, protein
content decreased during the course of treatment for all
genotypes resulting from exhaustion of mRNA reserves.
However, p.L217L showed slightly higher protein content
as compared with WT. To better delineate the cause for the
relative increase in protein levels after transcription block-
ade, we then quantified the proteins after translation inhi-
bition (cycloheximide). The p.L217L variant was associated
with a slowdown of protein degradation visible after 5–7 h
of treatment (Fig. 4d).
Effect of synonymous GATA2 c.649C>T variant on
zebrafish hematopoiesis
For further analysis we selected the c.649C>T, p.L217L
variant due to only partial reduction of the mutated allele
expression in hematopoietic specimen of the P4. We
hypothesized that the mutation may exert its effect on the
protein level and aimed to determine if it alters zebrafish
hematopoiesis. We used a previously published MO against
gata2b [35] and visualized hematopoietic stem and pro-
genitor cell (HSPC) in zebrafish embryos by whole-mount
in situ hybridization of the HSPC marker c-myb at 28 h post
fertilization, when HSPCs arise from the dorsal aorta.
Expectedly, gata2b inhibition resulted in a reduction of
HSPCs in zebrafish embryos (Fig. 5a, top right) [35]. We
then performed a phenotype rescue experiment by co-
injecting gata2b MO with human GATA2 WT or Mut
mRNA. Phenotype rescue (defined as medium/high phe-
notype; Supplementary Fig. 6) was achieved in 83% and
98% of embryos injected with WT and Mut mRNA,
respectively, (Fig. 5b–d). However, we observed a sig-
nificantly higher proportion of high phenotypes in animals
rescued with Mut mRNA (42%) as compared with WT
(19%), p < 0.05 (Fig. 5d right panel).
Discussion
GATA2 deficiency is a monogenic disorder known so far to
be caused by heterozygous nonsynonymous mutations,
whole gene deletions or intronic enhancer mutations, all of
which result in haploinsufficiency. In this study, we report
the identification of synonymous, RNA-deleterious
mutations in GATA2 that accounted for 8.2% of all
GATA2–mutated patients and 14.8% of cases with GATA2
exonic substitutions. In total, we identified nine patients
harboring five distinct synonymous GATA2 variants that are
either absent or exceedingly rare in general population: p.
T117T, p.P472P, p.L217L, p.G327G, and p.A341A. Two
of these (p.T117T and p.P472P) were encountered in mul-
tiple unrelated pedigrees, suggesting either independent
mutational events or rare founders in the European popu-
lation (which is possible at least for p.P472P present in
gnomAD in 23 individuals of non-Finnish European
ancestry). The phenotype of patients carrying synonymous
variants resembled GATA2 deficiency. All of the patients
were alive at last follow-up with exception of one patient
who died from HSCT-related complications. Additional
mutations in GATA2 were not identified. Other MDS-
predisposing conditions were excluded based on clinical
studies and WES/WGS in all patients with the exception of
P6 who carried two VUS in the SAMD9 gene. No specific
features demarcating GATA2 from SAMD9 syndrome were
present in this patient; hypospadias are unspecific and had
been reported in both conditions [36, 37]. At this point, we
cannot rule out that in P6 both gene defects acted in a
synergistic manner facilitating MDS development.
Computational prediction assigned an increased prob-
ability of missplicing to three of the five variants. Further
assessment of mutation deleteriousness with existing in silico
tools failed to ascribe pathogenic effects. Because of the
difficulty in predicting deleteriousness, synonymous muta-
tions have been generally left out in genomic studies.
However, it is likely that many disease-causing mutations are
being consistently overlooked—including mutations located
in noncoding regions of the genome as well as synonymous
variants. So far, little is known about the role of such
mutations in hematopoietic malignancies due to lack of
routine screening of the inter-/intragenic regions. Besides
known recurrent deleterious mutations in the regulatory
element of GATA2 [10] there are only few examples of
noncoding mutations associated with BMF. Recently, two
patients were reported with dyserythropoietic anemia and an
intronic substitution in GATA1 gene that is 24 nucleotides
upstream of the canonical splice acceptor site. This alteration
resulted in reduced canonical splicing and increased use of
an alternative splice acceptor site that causes a partial intron
retention event [38]. Moreover, mutations in 5’UTR and
deep intronic region of ELANE gene have been reported to
be associated with severe congenital neutropenia [39]. Due to
lack of studies integrating functional evaluation, the pre-
valence of such variants in Mendelian disorders is yet to be
determined. It is remarkable that recent pancancer studies
report acquired synonymous driver mutations at a rate of
~6–8% among all single-nucleotide changes found in human
cancers [40]. This is strikingly similar to the proportion of
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(germline) synonymous mutations identified in our study.
Mutations causing phenotypically severe hereditary disease
are mainly introduced as random de novo events, and it is
well accepted that purifying selection will eventually elim-
inate these deleterious alleles. This is especially valid in
high-penetrance conditions, such as GATA2 deficiency that
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Fig. 5 In vivo analysis of zebrafish hematopoiesis. a Whole-mount
in situ hybridization (WISH) performed at 28 h post fertilization (hpf)
for c-myb in embryos injected with control or gata2b morpholino
(MO). The arrows indicate the location of hematopoietic stem and
progenitor cells (HSPC) in the zebrafish aorta. The numbers in each
picture indicate the number of embryos with depicted phenotype out of
all embryos analyzed. b Rescue experiment performed on embryos co-
injected with gata2b MO and human GATA2 WT or Mut (c.649C>T)
mRNA. Transposase (TP) mRNA was used as a random control RNA
with no expected impact. A substantial number of the Mut (c.649C>T)
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control TP mRNA-injected siblings. c Graphical representation of the
rescue experiment. Distribution of phenotypes in all tested animals:
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Graphical representation of percentage of embryos with medium or
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often manifests before the reproductive age and thus results
in reduced fecundity.
There are multiple ways how synonymous substitutions
can exert deleteriousness even though the amino acid
sequence is not changed. As confirmed using three ortho-
gonal approaches, all of the mutations found here resulted in
a nearly complete and selective loss of the Mut transcript in
hematopoietic cells, with the exception of c.649C>T, p.
L217L that showed Mut allele reduction to ~20%. In con-
trast, paired analysis of two patients revealed a higher Mut
allele expression in skin fibroblasts versus hematopoietic
cells. Potential explanations for this discrepancy might be
the variability of allelic expression across different tissues
[41, 42] or the notion of context-dependent monoallelic
expression observed for ~20% of human genes [43]. In
addition, we observed that divergence in allelic ratio
depends not only on the tissue analyzed but also on the
stage of RNA processing. Strikingly, the mutation fre-
quency in BM of two patients (c.351C>G and c.1023C>T)
increased from nearly absent in mRNA to 30% in total RNA
transcripts, implying that the defect manifests at a late stage
of RNA maturation, at least for these two variants. Splicing
disruption was predicted for three variants (c.351C>G,
c.981G>A, and c.1023C>T); however, splicing analysis
confirmed novel splicing pattern only for c.351C>G. This
mutation resulted in aberrant transcripts with premature stop
codon which makes it functionally equivalent to a
frameshift-truncating mutation causing nonsense-mediated
decay. For the remaining four mutations, no abnormal
splicing was detected. It is conceivable that these Mut
mRNAs are extremely unstable and subjected to a very
rapid sequestration. Another potential explanation for loss
of allelic expression is epigenetic silencing that could arise
from aberrant promoter methylation. Supporting this, allelic
disbalance due to hypermethylation was recently observed
in one patient with GATA2 p.T354M mutation [44].
Synonymous variants can also affect translation and thus
result in increased or decreased protein stability or function.
Surprisingly, p.L217L Mut protein was slightly more stable
in vitro, although its function (tested in vitro using the
EMSA DNA gel shift assay at steady state, with ectopic
GATA2 overexpression) seemed not to be affected. Further,
this mutation not only rescued the GATA2-deficient phe-
notype in zebrafish, but also resulted in a significantly
higher number of HSPCs in comparison with control ani-
mals. Higher stability of this mutated protein might poten-
tially explain the relative increase in its functional properties
in vivo. In analogy, it is known that moderate GATA2
overexpression enhances proliferation and self-renewal of
progenitor cells [45]. We reason that the more efficient
rescue of the morphant phenotype can be associated with
higher stability of the p.L217L Mut, which is seen when
transiently overexpressed in 293T cell line (Fig. 4d).
Because of the challenging data (decrease of Mut RNA
expression but higher protein stability of protein) we do
question the pathogenicity of this mutation until additional
biological data or patients are reported. Limited availability
of patients’ primary specimens as well as instability of the
transcripts with synonymous mutations precluded further
mechanistic studies.
Reported diagnostic yields for WES/WGS in single
individuals can reach ~40% and heavily rely on compu-
tational predictions [46, 47] which are difficult to achieve
for synonymous mutations. Moreover, WES is limited to
the analysis of coding regions only. Even though genome
sequencing overcomes this constraint, it generates an
enormous output of alterations within coding and non-
coding regions of the genes. In setting of GATA2 defi-
ciency, WGS would facilitate the detection of pathogenic
intronic mutations in regulatory region in intron 4 (corre-
sponding to +9.5 kb enhancer region) as well as whole
gene and partial gene deletions. However, allelic loss on
RNA level would be missed. The utility of transcriptome
analysis was previously highlighted by the identification of
disease-causing mutations in patients with negative exome
or genome sequencing results, increasing the diagnostic
rate by as much as 35% [48, 49]. Hence, we propose that
diagnostic sequencing should incorporate a cascade
approach where RNA sequencing follows inconclusive
DNA analysis in patients with suspected disease. This
approach is feasible not only for patients with GATA2
deficiency but also in patients with high index of suspicion
for a specific Mendelian disorder but without a known
pathogenic mutation. Our findings suggest that a straight-
forward Sanger or deep sequencing of cDNA would be
sufficient to confirm the RNA-deleteriousness of a
synonymous variant.
In summary, we demonstrate that a significant pro-
portion of GATA2-deficient patients carry damaging
synonymous alterations. These genetic changes, pre-
viously excluded from analysis due to their likely silent
effect, should be incorporated into standard diagnostic
pipeline for individuals with GATA2 disease phenotype.
However, patients with other hereditary BM failure and
MDS syndromes might also benefit from this extended
diagnostic approach. In the long term, identification of
pathogenic synonymous variants has the potential to
improve genetic counseling, HSCT donor selection, and
clinical outcomes.
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